1E Therapeutics announced $120 million seed funding, a remarkable feat for an early-stage biotech company. The funding is the largest of its kind for an Israeli biotech company.

Instead of letting LinkedIn slide to the bottom of your to-do list day after day, block off an hour on your calendar once a week to create a post and engage with your connections.

Deciding on when to switch your job can be a difficult decision to make.

At Harbinger, Hahn will oversee the development of the Bio-AI diagnostics platform dubbed HarbingerHx, in hopes of detecting cancer in a patient before it is visible or symptomatic.

Newpath is guided by the ethos: “Do the right thing and good things will happen."

The company could lay off as many as 1,000 employees as it continues to deal with the controversial treatment.

On Wednesday, clinical-stage biotech Avistone Pharmaceuticals announced that it has raised more than $200 million of financial backing to support its business combination with Pearl Biotechnology.

Several life sciences companies and life science-focused real estate firms have announced expansion plans as 2021 comes to an end.

The counterclaim by an alleged victim of MIT professor David Sabatini said she was coerced into sex and that Sabatini's laboratory had a “toxic and sexually charged” environment.

​Known as the Reproducibility Project: Cancer Biology, it spent eight years replicating experiments from high-impact cancer biology papers published between 2010 and 2012.

LAG-3 is a priority focus in cancer immunotherapy because its inhibition has the potential to make PD-1 inhibitors work in more patients.

​Neurocrine Biosciences and Acadia Pharmaceuticals posted positive top-line results from their respective Phase III trials on major neurological diseases.

Pfizer's preliminary laboratory studies have shown that the third booster dose increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant.

Vyera Pharmaceuticals agreed to pay $40 million to settle federal allegations to radically increase the price of toxoplasmosis drug Daraprim and prevent generic competition.

​Biopharmaceutical firm Alvotech Holdings announced merger plans with Oaktree Acquisition Corp. in a deal that will create a combined entity worth around $2.25 billion.

The news comes just three weeks after Merck paused its Phase II IMAGINE-DR trial, which was studying a combination of islatravir with MK-8507.

Odyssey Therapeutics completed an oversubscribed $218 million Series A round. The funds will be used to advance multiple programs from its pipeline and its discovery platform.

Recursion entered into a billion-dollar “transformational collaboration” with Roche to identify and develop up to 40 new medications for neuroscience and oncology.

Despite having 37 new mutations in the viral spike protein, there does not appear to be any deaths associated with Omicron, although it’s spreading rapidly in South Africa.

The Cambridge, Massachusetts-based company has developed an artificial intelligence platform designed to optimize pharmaceutical formulation processes.